Yu NY, Iftimi A, Yau C, et al. - Through the secondary analysis of the Stockholm Tamoxifen trial of 462 postmenopausal patients with lymph node-negative breast cancer, experts contrasted the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype. A statistically important variation in the distant recurrence-free interval by trial arm was noted. Patients with luminal A tumors significantly profited from tamoxifen therapy for 15 years following diagnosis, and those with luminal B tumors profited from tamoxifen therapy for 5 years. Therefore, long-term risk of distant metastatic disease was observed in patients with luminal A subtype tumors which was decreased by tamoxifen treatment, whereas patients with luminal B tumors had an early risk of distant metastatic disease, and tamoxifen advantage attenuated over time.